Article
24 Jul 2025
The CRISPR Patent Wars Hit Japan: A High-Stakes Battle Over Gene-Editing's Future
AUTHORS CONTENT
Article
16 Jul 2025
まさかの特許バトル：たったこれだけの投与変更が数十億ドルに
Article
16 Jul 2025
Not So Obvious: You Won't Believe How This Simple Dosing Change Became Worth Billions
Article
03 Jun 2025
SCOTUSblog Founder Plays Deft Hand In Own Defense Against Tax Evasion Charges
Article
05 May 2025
The DOGE Analyst Returns To YOUR Law Firm To Discuss The Rise Of Non-Equity Partners: A Sequel
Article
26 Mar 2025
What If DOGE Paid A Visit To YOUR Law Firm?
Article
07 Mar 2025
DOGE Unleashed: If PwC Can Do It, Then Why Not DOGE?
Article
06 Mar 2025
The Post-Chevron Pendulum: From Judicial Deference To Dominance In New York State v. Trump
Article
20 Feb 2025
Who Controls The Bureaucracy? The Supreme Court's Next Landmark Executive Power Case
Article
18 Feb 2025
Collateral Estoppel At A Crossroads: When IPR Invalidity Determinations Do And Don't Preclude District Court Litigation
Article
13 Feb 2025
Pardon Me? Why Your Assets Might Not Be So Lucky
Article
03 Jan 2025
No Drug? No Dice! Clarifying Orange Book Eligibility For Drug-Device Patents
Article
02 Jan 2025
Combining References In IPRs: Lessons From The Federal Circuit's Latest Rulings
Article
23 Dec 2024
When Inherency Meets Obvious-to-Try: How Cytiva V. JSR Clarifies The Patent Obviousness Analysis
Article
23 Dec 2024
Speaking Too Soon: How An Early Price Quotation Cost Crown A Patent
Article
02 Dec 2024
Philip Morris Smokes Healthier Choices In IPR: The Federal Circuit Weighs In On Negative Claim Limitations
Article
10 Oct 2024
In Vivo Production And Patent Infringement—An Issue Of First Impression In Japan's IP High Court
Article
23 Sep 2024
Taxation Of Tip Income—The Untold Story
Article
09 Sep 2024
WARF v. Apple Reaffirms Kessler Doctrine: Protecting Products From Duplicative Patent Litigation
Article
22 Aug 2024
When Patent Term Adjustment Meets Obviousness-Type Double Patenting: New Insights From Allergan v. MSN